After at least one prior line of therapy,
Unlock the power of BLENREP in combination therapy
For relapsed or refractory multiple myeloma
PrBLENREP (belantamab mafodotin for injection) is indicated in combination with1:
- bortezomib and dexamethasone (BVd) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy
- pomalidomide and dexamethasone (BPd) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide
BLENREP combination therapy was evaluated across key efficacy endpoints in two pivotal Phase 3 trials1:
- Progression-free survival (PFS)
- Overall survival (OS)
- Response rates and minimal residual disease
-
Efficacy data
BLENREP combination therapy was evaluated in DREAMM-7 and DREAMM-8 — two pivotal Phase 3 trials.
Explore the efficacy data -
Safety data
Review the BLENREP safety profile, eye-related side effects, and supportive eye-care management.
Explore the safety profile -
Dosing & administration
BLENREP combination dosing across the BVd and BPd regimens — starting dose, modifications, and administration.
Explore dosing & administration
Patient profiles
Three fictitious profiles spanning different ages, transplant statuses, and comorbidities — illustrating BLENREP combination therapy considerations across a range of patient types with relapsed or refractory multiple myeloma.*
-
Meet Bryant*
59-year-old male · Diagnosed with MM 5 years ago.
Learn more -
Meet Bonnie*
67-year-old female · Diagnosed with MM 4 years ago.
Learn more -
Meet Beatrice*
70-year-old female · Diagnosed with MM 8 years ago.
Learn more
*Fictitious patients. May not be representative of all patients.
Consider BLENREP for your eligible patients
Need more information about BLENREP?
Reference
- Current BLENREP Product Monograph. GlaxoSmithKline Inc.